Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.01
- Piotroski Score 1.00
- Grade Buy
- Symbol (ALEC)
- Company Alector, Inc.
- Price $3.95
- Changes Percentage (5.05%)
- Change $0.19
- Day Low $3.75
- Day High $3.98
- Year High $8.90
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $4.00
- High Stock Price Target $4.00
- Low Stock Price Target $4.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.39
- Trailing P/E Ratio -3.14
- Forward P/E Ratio -3.14
- P/E Growth -3.14
- Net Income $-130,391,000
Income Statement
Quarterly
Annual
Latest News of ALEC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Alec Baldwin's "Rust" to premiere after deadly shooting on set over 3 years ago
The western film "Rust," directed by Alec Baldwin, will air despite a tragic incident where a live round in a prop gun killed a cinematographer. Director Joel Souza, injured in the shooting, discussed...
By CBS News | 2 days ago -
Alec Baldwin's 'Rust,' Marked by Tragedy, Nears Premiere in Poland
Alec Baldwin's film "Rust" faces a premiere at the Camerimage festival in Poland after a tragic on-set shooting in 2021. The completion of the movie involved significant changes and legal implications...
By The New York Times | 2 days ago -
Mother of cinematographer killed on set of Alec Baldwin film 'Rust' boycotts its world premiere
Halyna Hutchins' mother boycotts the premiere of "Rust" at a film festival in Poland, accusing Alec Baldwin of profiting from her daughter's death. The event at the Camerimage festival is dedicated to...
By AP NEWS | 2 days ago
